Exclusion criteria included patients with type 1 DM, chronic kidney disease, congestive heart failure, recent ischemic attacks, hepatic cell failure, SGLT2 (Sodium-glucose Cotransporter-2) inhibitors users and pregnant females. This evidence concerns the gene SLC5A2 and congestive heart failure.